• Med. J. Aust. · Feb 1985

    Vindesine in the treatment of refractory haematological malignant diseases.

    • G A Young, J Jurd, and P C Vincent.
    • Med. J. Aust. 1985 Feb 4; 142 (3): 189-90.

    AbstractVindesine, a cytotoxic drug related to vincristine and vinblastine, was used in the treatment of refractory haematological malignant disease in 25 patients. Short-term benefits such as the lowering of leukaemic blast-cell counts and the alleviation of symptoms, particularly resolution of bone pain, were observed in some patients; however, long-term benefit was elusive. In general, the drug was well tolerated, and it was possible to administer vindesine without further neurological toxicity to some patients who previously had suffered from neuropathy. Vindesine may well have a place in the treatment of tumours which respond to vinca-alkaloid therapy in patients in whom previous therapy has produced neurotoxicity, and for the relief of troublesome symptoms, particularly bone pain, in heavily pretreated patients.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.